Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Drug Costs"" wg kryterium: Temat


Tytuł :
Variation in the availability and cost of essential medicines for non-communicable diseases in Uganda: A descriptive time series analysis.
Autorzy :
Armstrong-Hough M; School of Global Public Health, New York University, New York, NY, United States of America.
Sharma S; Wake Forest School of Medicine, Winston-Salem, NC, United States of America.
Kishore SP; Arnhold Institute for Global Health, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America.; Young Professionals Chronic Disease Network, New York, New York, United States of America.
Akiteng AR; Uganda Initiative for Integrated Management of Non-Communicable Diseases, Kampala, Uganda.
Schwartz JI; Uganda Initiative for Integrated Management of Non-Communicable Diseases, Kampala, Uganda.; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States of America.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Dec 23; Vol. 15 (12), pp. e0241555. Date of Electronic Publication: 2020 Dec 23 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Costs*/trends
Drugs, Essential/*economics
Drugs, Essential/*supply & distribution
Noncommunicable Diseases/*drug therapy
Communicable Diseases/drug therapy ; Communicable Diseases/economics ; Health Facilities/economics ; Health Services Accessibility/economics ; Health Services Accessibility/trends ; Humans ; Noncommunicable Diseases/economics ; Private Sector/economics ; Prospective Studies ; Public Sector/economics ; Surveys and Questionnaires ; Time Factors ; Uganda
Czasopismo naukowe
Tytuł :
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach.
Autorzy :
Barber MRW; University of Calgary, Alberta, Canada.
Hanly JG; Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.
Su L; University of Cambridge, Cambridge, UK.
Urowitz MB; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
St Pierre Y; Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.
Romero-Diaz J; Instituto Nacional de Ciencias Médicas y Nutricion, Mexico City, Mexico.
Gordon C; University of Birmingham, Birmingham, UK.
Bae SC; Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea.
Bernatsky S; McGill University Health Centre, Montreal, Quebec, Canada.
Wallace DJ; Cedars-Sinai Medical Center and University of California, Los Angeles.
Merrill JT; Oklahoma Medical Research Foundation, Oklahoma City.
Isenberg DA; University College London, London, UK.
Rahman A; University College London, London, UK.
Ginzler EM; State University of New York Downstate Medical Center, Brooklyn.
Petri M; Johns Hopkins University School of Medicine, Baltimore, Maryland.
Bruce IN; Manchester Academic Health Sciences Centre, University of Manchester and Central Manchester University Hospitals National Health Service Foundation Trust, Manchester, UK.
Dooley MA; University of North Carolina, Chapel Hill.
Fortin PR; CHU de Québec, Université Laval, Quebec City, Quebec, Canada.
Gladman DD; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
Sanchez-Guerrero J; Toronto Western Hospital and University of Toronto, Toronto, Ontario, Canada.
Steinsson K; Landspitali University Hospital, Reykjavik, Iceland.
Ramsey-Goldman R; Northwestern University, Chicago, Illinois.
Khamashta MA; St. Thomas' Hospital, King's College London, London, UK.
Aranow C; Feinstein Institutes for Medical Research, Manhasset, New York.
Mackay M; Feinstein Institutes for Medical Research, Manhasset, New York.
Alarcón GS; University of Alabama at Birmingham.
Manzi S; University of Pittsburgh, Pittsburgh, Pennsylvania.
Nived O; Lund University, Lund, Sweden.
Jönsen A; Lund University, Lund, Sweden.
Zoma AA; Hairmyres Hospital, East Kilbride, Scotland, UK.
van Vollenhoven RF; University of Amsterdam, Amsterdam, The Netherlands.
Ramos-Casals M; Hospital Clinic of Barcelona, Barcelona, Spain.
Ruiz-Irastorza G; Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.
Lim SS; Emory University, Atlanta, Georgia.
Kalunian KC; University of California Los Angeles, La Jolla.
Inanc M; Istanbul University, Istanbul, Turkey.
Kamen DL; Medical University of South Carolina, Charleston.
Peschken CA; University of Manitoba, Winnipeg, Manitoba, Canada.
Jacobsen S; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Askanase A; Hospital for Joint Diseases, New York University Seligman Center for Advanced Therapeutics, New York, New York.
Farewell V; University of Cambridge, Cambridge, UK.
Stoll T; Kantousspital, Schaffhausen, Switzerland.
Buyon J; New York University, New York, New York.
Clarke AE; University of Calgary, Alberta, Canada.
Pokaż więcej
Źródło :
Arthritis care & research [Arthritis Care Res (Hoboken)] 2020 Dec; Vol. 72 (12), pp. 1800-1808.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Costs*
Antirheumatic Agents/*economics
Antirheumatic Agents/*therapeutic use
Glucocorticoids/*economics
Glucocorticoids/*therapeutic use
Immunosuppressive Agents/*economics
Immunosuppressive Agents/*therapeutic use
Lupus Erythematosus, Systemic/*drug therapy
Lupus Erythematosus, Systemic/*economics
Adult ; Antirheumatic Agents/adverse effects ; Cost-Benefit Analysis ; Disease Progression ; Female ; Glucocorticoids/adverse effects ; Humans ; Immunosuppressive Agents/adverse effects ; Longitudinal Studies ; Lupus Erythematosus, Systemic/diagnosis ; Male ; Middle Aged ; Models, Economic ; Remission Induction ; Time Factors ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
[Cost/benefit analysis of cancer drugs].
Autorzy :
Jordan B; UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS ; CoReBio PACA, case 901, Parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
Pokaż więcej
Transliterated Title :
Bénéfice clinique et coût des traitements anticancéreux.
Źródło :
Medecine sciences : M/S [Med Sci (Paris)] 2020 Nov; Vol. 36 (11), pp. 1095-1097. Date of Electronic Publication: 2020 Nov 05.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Costs*
Antineoplastic Agents/*economics
Antineoplastic Agents/*therapeutic use
Cost-Benefit Analysis ; Drug Industry/economics ; Drug Industry/ethics ; Drug Industry/standards ; Drug Industry/statistics & numerical data ; Ethics, Pharmacy ; Europe/epidemiology ; Health Care Costs ; Humans ; Neoplasms/drug therapy ; Neoplasms/economics ; Neoplasms/epidemiology ; United States/epidemiology
Czasopismo naukowe
Tytuł :
A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians and society, part 1.
Autorzy :
Burns TM; Department of Neurology, University of Virginia, Charlottesville, Virginia, USA.
Crowell JL; Beth Israel Deaconess Medical Center, Jerome H. Grossman M.D. Graduate Fellow, Harvard Kennedy School, Boston, Massachusetts, USA.
Smith AG; Department of Neurology, Virginia Commonwealth University, Richmond, Virginia, USA.
Pokaż więcej
Źródło :
Muscle & nerve [Muscle Nerve] 2020 Nov; Vol. 62 (5), pp. 567-572. Date of Electronic Publication: 2020 Jul 28.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Costs*
Neuromuscular Diseases/*drug therapy
Neuromuscular Diseases/*economics
Orphan Drug Production/*economics
Prescription Drugs/*economics
Drugs, Generic/economics ; Humans ; Physicians ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
A crisis in US drug pricing: Consequences for patients with neuromuscular diseases, physicians, and society, part 2.
Autorzy :
Burns TM; Department of Neurology, University of Virginia, Charlottesville, VA, USA.
Crowell JL; Beth Israel Deaconess Medical Center, Jerome H. Grossman M.D. Graduate Fellow, Harvard Kennedy School, Boston, MA, USA.
Smith AG; Department of Neurology, Virginia Commonwealth University, Richmond, VA, USA.
Pokaż więcej
Źródło :
Muscle & nerve [Muscle Nerve] 2020 Nov; Vol. 62 (5), pp. 573-578. Date of Electronic Publication: 2020 Jul 29.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Costs*
Neuromuscular Diseases/*drug therapy
Neuromuscular Diseases/*economics
Prescription Drugs/*economics
Clinical Decision-Making/ethics ; Humans ; Physicians ; United States
Czasopismo naukowe
Tytuł :
Exploring the Economic Benefits of Modafinil for Post-Stroke Fatigue in Australia: A Cost-Effectiveness Evaluation.
Autorzy :
Bajorek B; Academic Pharmacist - Graduate School of Health, University of Technology Sydney, Broadway, New South Wales 2007, Australia; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia. Electronic address: .
Gao L; Senior Lecturer - Deakin Health Economics, Institute for Health Transformation, Deakin University, Geelong, Victoria 3127, Australia. Electronic address: .
Lillicrap T; Academic Pharmacist - Graduate School of Health, University of Technology Sydney, Broadway, New South Wales 2007, Australia; Clinical Scientist - Neurology Department, John Hunter Hospital, New Lambton Heights, New South Wales 2305, Australia. Electronic address: .
Bivard A; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia; Principle Research Fellow - Melbourne School of Health Sciences - Faculty of Medicine, Dentistry and Health Sciences, Victoria, Australia. Electronic address: .
Garcia-Esperon C; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia; Stroke Neurologist - Department of Neurology, John Hunter Hospital, New Lambton Heights, New South Wales 2305, Australia. Electronic address: .
Parsons M; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia; Director of Neurology - Department of Neurology, Royal Melbourne Hospital, Parkville, Victoria 3052, Australia. Electronic address: .
Spratt N; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia; Stroke Neurologist - Department of Neurology, John Hunter Hospital, New Lambton Heights, New South Wales 2305, Australia; School of Biomedical Sciences, University of Newcastle, Australia. Electronic address: .
Holliday E; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia; School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales 2308, Australia. Electronic address: .
Levi C; Research Affiliate - Hunter Medical Research Institute, New South Wales, Australia; The Sydney Partnership for Health, Education, Research, and Enterprise (SPHERE), Liverpool, New South Wales 2170, Australia. Electronic address: .
Pokaż więcej
Źródło :
Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association [J Stroke Cerebrovasc Dis] 2020 Nov; Vol. 29 (11), pp. 105213. Date of Electronic Publication: 2020 Aug 08.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Costs*
Central Nervous System Stimulants/*economics
Central Nervous System Stimulants/*therapeutic use
Fatigue/*drug therapy
Fatigue/*economics
Modafinil/*economics
Modafinil/*therapeutic use
Stroke/*economics
Stroke/*therapy
Aged ; Australia ; Central Nervous System Stimulants/adverse effects ; Clinical Trials, Phase II as Topic ; Cost Savings ; Cost-Benefit Analysis ; Fatigue/diagnosis ; Fatigue/physiopathology ; Female ; Humans ; Male ; Middle Aged ; Modafinil/adverse effects ; Quality of Life ; Quality-Adjusted Life Years ; Randomized Controlled Trials as Topic ; Recovery of Function ; Stroke/diagnosis ; Stroke/physiopathology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study.
Autorzy :
Napoli R; Department of Translational Medical Sciences, Federico II University School of Medicine, Naples, Italy.
Fanelli F; Sanofi S.p.A, Milan, Italy.
Gazzi L; Sanofi S.p.A, Milan, Italy.
Larosa M; Sanofi S.p.A, Milan, Italy.
Bitonti R; EBMA Consulting, Melegnano, Milan, Italy.
Furneri G; EBMA Consulting, Melegnano, Milan, Italy. Electronic address: .
Pokaż więcej
Źródło :
Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2020 Oct 30; Vol. 30 (11), pp. 1937-1944. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Costs*
Diabetes Mellitus, Type 2/*drug therapy
Diabetes Mellitus, Type 2/*economics
Glycemic Control/*economics
Hypoglycemic Agents/*economics
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*economics
Insulin Glargine/*therapeutic use
Insulin, Long-Acting/*economics
Insulin, Long-Acting/*therapeutic use
Biomarkers/blood ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; Budgets ; Cost Savings ; Cost-Benefit Analysis ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/diagnosis ; Glycemic Control/adverse effects ; Humans ; Hypoglycemic Agents/adverse effects ; Insulin Glargine/adverse effects ; Insulin, Long-Acting/adverse effects ; Italy ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[The sustainability of the health system and the pharmaceutical market: A permanent interaction between the cost of medications, the patent system, and disease care].
Autorzy :
Gómez Franco T; Doctor en Economía aplicada. Profesor de Economía, Universidad Carlos III de Madrid, Madrid, España. .
Matarín Rodríguez-Peral E; Doctora en Ciencias de la Información. Profesora del área de sociología, Universidad Rey Juan Carlos, Madrid, España. .
García García F; Doctor en Ciencias de la Información. Profesor Catedrático de Comunicación Audiovisual y Publicidad, Universidad Complutense de Madrid, Madrid, España. .
Pokaż więcej
Transliterated Title :
La sostenibilidad del sistema de salud y el mercado farmacéutico: Una interacción permanente entre el costo de los medicamentos, el sistema de patentes y la atención a las enfermedades.
Źródło :
Salud colectiva [Salud Colect] 2020 Oct 17; Vol. 16, pp. e2897. Date of Electronic Publication: 2020 Oct 17.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/economics
Antiviral Agents*/therapeutic use
Drug Costs*
Health Policy*
Patents as Topic*
Drug Industry/*organization & administration
Health Services Accessibility/*organization & administration
Virus Diseases/*drug therapy
Drugs, Generic ; Global Health ; Humans ; Pandemics ; Program Evaluation ; Virus Diseases/economics ; Virus Diseases/epidemiology ; Virus Diseases/prevention & control
Czasopismo naukowe
Tytuł :
Application of KW-ANOVA statistics to generate evidence for cytotoxic drug wastage induced financial burden among cancer patients: A clinical pharmacist observation.
Autorzy :
Jyoti K; Department of Pharmacy Practice, KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
Manjula G; Department of Pharmacy Practice, KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
Ganachari MS; Department of Pharmacy Practice, KLE College of Pharmacy, KAHER, Belagavi, Karnataka, India.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Oct; Vol. 26 (7), pp. 1559-1565. Date of Electronic Publication: 2020 Jan 16.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Drug Costs*
Pharmacists*
Antineoplastic Agents/*therapeutic use
Neoplasms/*drug therapy
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; Child ; Female ; Humans ; Male ; Middle Aged ; Pharmacies/economics ; Prospective Studies ; Quality of Life ; Young Adult
Czasopismo naukowe
Tytuł :
Centralization impact and cost-saving study in a Moroccan hospital's centralized unit of chemotherapy preparation.
Autorzy :
Adade CA; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.; Ibn Sina University Hospital, Rabat, Morocco.
Benabbes M; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.; Ibn Sina University Hospital, Rabat, Morocco.
Belahcen MJ; National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco.
Rahali Y; Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.; National Institute of Oncology, Ibn Sina University Hospital, Rabat, Morocco.; Team of Formulation and Quality Control of Health Products, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Oct; Vol. 26 (7), pp. 1630-1636. Date of Electronic Publication: 2020 Feb 11.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Costs*
Income*
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents/economics ; Hospitals ; Humans ; Prospective Studies
Czasopismo naukowe
Tytuł :
The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model.
Autorzy :
Lodise TP; Albany College of Pharmacy and Health Sciences, Albany, NY, USA.
Tillotson GS; GST Micro LLC, Henrico, VA, USA.
Spargo A; Xcenda, Tampa, FL, USA.
Bozkaya D; Xcenda, Tampa, FL, USA.
Massey J; Melinta Therapeutics, Inc., Morristown, NJ, USA. .; Immunomedics, Inc., Morris Plains, NJ, USA. .
Pokaż więcej
Źródło :
Clinical drug investigation [Clin Drug Investig] 2020 Oct; Vol. 40 (10), pp. 961-971.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Costs*
Anti-Bacterial Agents/*therapeutic use
Community-Acquired Infections/*drug therapy
Fluoroquinolones/*therapeutic use
Pneumonia, Bacterial/*drug therapy
Adult ; Anti-Bacterial Agents/economics ; Fluoroquinolones/economics ; Humans ; Models, Economic ; Moxifloxacin ; Outpatients
Czasopismo naukowe
Tytuł :
Association Between the Percentage of US Drug Sales Subject to Inflation Penalties and the Extent of Drug Price Increases.
Autorzy :
Dickson S; West Health Policy Center, Washington, DC.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2020 Sep 01; Vol. 3 (9), pp. e2016388. Date of Electronic Publication: 2020 Sep 01.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Costs/*statistics & numerical data
Inflation, Economic/*statistics & numerical data
Commerce/statistics & numerical data ; Commerce/trends ; Cross-Sectional Studies ; Drug Costs/trends ; Humans ; Inflation, Economic/trends ; Medicare Part D/economics ; Medicare Part D/statistics & numerical data ; United States
Czasopismo naukowe
Tytuł :
Research and Development Costs of New Drugs-Reply.
Autorzy :
Wouters OJ; Department of Health Policy, London School of Economics and Political Science, London, United Kingdom.
McKee M; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Luyten J; Department of Public Health and Primary Care, Leuven Institute for Healthcare Policy, Leuven, Belgium.
Pokaż więcej
Źródło :
JAMA [JAMA] 2020 Aug 04; Vol. 324 (5), pp. 518.
Typ publikacji :
Journal Article; Comment
MeSH Terms :
Drug Costs*
Research*
Costs and Cost Analysis
Czasopismo naukowe
Tytuł :
Research and Development Costs of New Drugs.
Autorzy :
Dominguez LW; Department of Emergency Medicine, The George Washington University Medical Faculty Associates, Washington, DC.
Willis JS; Department of Emergency Medicine, The George Washington University Medical Faculty Associates, Washington, DC.
Pokaż więcej
Źródło :
JAMA [JAMA] 2020 Aug 04; Vol. 324 (5), pp. 516.
Typ publikacji :
Letter; Comment
MeSH Terms :
Drug Costs*
Investments*
Costs and Cost Analysis
Opinia redakcyjna
Tytuł :
A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Autorzy :
Davis LE; Midwestern University College of Pharmacy, 19555 North 59th Avenue, Glendale, AZ, 85308, USA.
Pogge EK; Midwestern University College of Pharmacy, 19555 North 59th Avenue, Glendale, AZ, 85308, USA. .
Pokaż więcej
Źródło :
High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension [High Blood Press Cardiovasc Prev] 2020 Aug; Vol. 27 (4), pp. 331-338. Date of Electronic Publication: 2020 Jul 10.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Costs*
Anticholesteremic Agents/*economics
Anticholesteremic Agents/*therapeutic use
Atherosclerosis/*drug therapy
Atherosclerosis/*economics
Cholesterol, LDL/*blood
Hyperlipoproteinemia Type II/*drug therapy
Hyperlipoproteinemia Type II/*economics
Proprotein Convertase 9/*antagonists & inhibitors
Serine Proteinase Inhibitors/*economics
Serine Proteinase Inhibitors/*therapeutic use
Age Factors ; Aged ; Aged, 80 and over ; Anticholesteremic Agents/adverse effects ; Atherosclerosis/blood ; Atherosclerosis/diagnosis ; Biomarkers/blood ; Down-Regulation ; Female ; Health Expenditures ; Humans ; Hyperlipoproteinemia Type II/blood ; Hyperlipoproteinemia Type II/diagnosis ; Insurance, Pharmaceutical Services/economics ; Male ; Proprotein Convertase 9/metabolism ; Retrospective Studies ; Serine Proteinase Inhibitors/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Delivering Benefits at Speed Through Real-World Repurposing of Off-Patent Drugs: The COVID-19 Pandemic as a Case in Point.
Autorzy :
Rogosnitzky M; MedInsight Research Institute, Rehovot, Israel.
Berkowitz E; MedInsight Research Institute, Rehovot, Israel.
Jadad AR; Program in Impactful Giving, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.; Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło :
JMIR public health and surveillance [JMIR Public Health Surveill] 2020 May 13; Vol. 6 (2), pp. e19199. Date of Electronic Publication: 2020 May 13.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Coronavirus*/drug effects
Coronavirus*/isolation & purification
Drug Costs*
Drug Repositioning*
Drugs, Generic*
Off-Label Use*
Pandemics*
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Humans ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; Public Health ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
[Biosimilars: opportunities and risks].
Autorzy :
Grieshaber-Bouyer R; Medizinische Klinik V, Klinik für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland. .
Lorenz HM; Medizinische Klinik V, Klinik für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
Pokaż więcej
Transliterated Title :
Biosimilars – Chancen und Risiken.
Źródło :
Der Internist [Internist (Berl)] 2020 May; Vol. 61 (5), pp. 522-529.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Approval*
Drug Costs*
Biological Products/*therapeutic use
Biosimilar Pharmaceuticals/*therapeutic use
Biological Products/economics ; Biosimilar Pharmaceuticals/economics ; Germany ; Humans
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies